Milestone Pharmaceuticals Inc. (MIST) Financial Statements (2026 and earlier)

Company Profile

Business Address 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420
MONTREAL, QC H4M 2X6
State of Incorp. QC
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:69,700,00066,000,00064,500,000114,100,000142,300,000119,818,000
Cash and cash equivalent25,314,00013,760,0007,636,000114,141,00072,310,000119,818,000
Short-term investments44,381,00052,243,00056,949,000 70,000,000 
Other undisclosed cash, cash equivalents, and short-term investments5,000(3,000)(85,000)(41,000)(10,000) 
Receivables1,490,0003,208,000882,000127,000223,000258,000
Prepaid expense1,840,0003,178,0006,005,0004,299,0005,428,0001,845,000
Other undisclosed current assets896,000646,000416,000397,000735,000578,000
Total current assets:73,926,00073,032,00071,803,000118,923,000148,686,000122,499,000
Noncurrent Assets
Operating lease, right-of-use asset1,376,0001,917,0002,423,000711,000980,000524,000
Property, plant and equipment197,000277,000257,000215,000308,000405,000
Total noncurrent assets:1,573,0002,194,0002,680,000926,0001,288,000929,000
TOTAL ASSETS:75,499,00075,226,00074,483,000119,849,000149,974,000123,428,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:7,555,0006,680,0005,644,0006,551,0005,914,0007,997,000
Employee-related liabilities1,458,000957,0001,777,000
Accounts payable1,932,0003,981,0002,263,0004,384,0004,641,0004,376,000
Accrued liabilities3,057,0001,095,0002,977,000437,000164,000331,000
Other undisclosed accounts payable and accrued liabilities2,566,0001,604,000404,000272,000152,0001,513,000
Debt      330,000
Other undisclosed current liabilities571,000546,000495,000224,000245,000 
Total current liabilities:8,126,0007,226,0006,139,0006,775,0006,159,0008,327,000
Noncurrent Liabilities
Long-term debt and lease obligation:    474,000696,000184,000
Liabilities, other than long-term debt874,0001,457,0001,996,000   
Operating lease, liability874,0001,457,0001,996,000474,000696,000184,000
Other undisclosed noncurrent liabilities53,352,00049,772,000 (474,000)(696,000) 
Total noncurrent liabilities:54,226,00051,229,0001,996,000474,000696,000184,000
Total liabilities:62,352,00058,455,0008,135,0007,249,0006,855,0008,511,000
Equity
Equity, attributable to parent13,147,00016,771,00066,348,000112,600,000143,119,000114,917,000
Common stock288,048,000260,504,000273,900,000251,901,000251,682,000226,245,000
Additional paid in capital39,568,00033,834,00024,437,00015,711,0008,530,0003,805,000
Accumulated other comprehensive loss    (1,634,000)(1,634,000)(1,634,000)
Accumulated deficit(367,545,000)(326,026,000)(266,341,000)(206,319,000)(163,466,000)(113,499,000)
Warrants and rights outstanding53,076,00048,459,00034,352,00052,941,00048,007,000 
Total equity:13,147,00016,771,00066,348,000112,600,000143,119,000114,917,000
TOTAL LIABILITIES AND EQUITY:75,499,00075,226,00074,483,000119,849,000149,974,000123,428,000

Income Statement (P&L) (USD)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(31,099,000)(46,984,000)(55,547,000)(51,070,000)(44,773,000)(48,989,000)
Other undisclosed operating income (loss)(11,003,000)(14,114,000)(4,095,000)7,997,000(5,937,000)(8,892,000)
Operating loss:(42,102,000)(61,098,000)(59,642,000)(43,073,000)(50,710,000)(57,881,000)
Nonoperating income
(Investment Income, Nonoperating)
4,164,000  220,000726,0002,596,000
Interest and debt expense(3,581,000)(2,554,000)    
Loss from continuing operations before equity method investments, income taxes:(41,519,000)(63,652,000)(59,642,000)(42,853,000)(49,984,000)(55,285,000)
Other undisclosed income from continuing operations before income taxes  3,967,0001,254,000   
Loss from continuing operations before income taxes:(41,519,000)(59,685,000)(58,388,000)(42,853,000)(49,984,000)(55,285,000)
Income tax benefit     17,00056,000
Loss from continuing operations:(41,519,000)(59,685,000)(58,388,000)(42,853,000)(49,967,000)(55,229,000)
Loss before gain (loss) on sale of properties:(42,853,000)(49,967,000)(55,229,000)
Net loss available to common stockholders, diluted:(41,519,000)(59,685,000)(58,388,000)(42,853,000)(49,967,000)(55,229,000)

Comprehensive Income (USD)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(41,519,000)(59,685,000)(58,388,000)(42,853,000)(49,967,000)(55,229,000)
Comprehensive loss, net of tax, attributable to parent:(41,519,000)(59,685,000)(58,388,000)(42,853,000)(49,967,000)(55,229,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: